ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite Mayfair district in February to take part in the ‘Dragons Den’ of veterinary medicine, the European Animal Health Investment Forum.

This will be ARTES’ first participation in the high prestige investment networking event.

ARTES will be represented by its Managing Director, Dr. Michael Piontek, who will be talking in particular about the development of its innovative proprietary vaccine development platform, METAVAX®.


METAVAX® generates vaccines based on the WHO-recommended yeast organism Hansenula polymorpha.

ARTES Biotechnology also has expertise in human and animal vaccine development and is collaborating with animal health leader Boehringer Ingelheim to develop  a vaccine based on Hansenula polymorpha expression, combined with the METAVAX® platform

Self-adjuvanting vaccines

“We look forward to attending the European Animal Health Investment Forum for the opportunity to network with CEOs, business developers and scientists from veterinary pharmaceutical companies interested in development of highly immunogenic vaccines,” commented Dr. Piontek.

“This is a great opportunity to find new contacts, refresh old ones and show how we have developed an economical approach for low-cost mass production of safe, effective and self-adjuvanting vaccines,” said Dr. Piontek.

ARTES will also use the meeting to share knowledge about its VLP technology for antigen presentation and other vaccine technologies.  It will also exchange information on its specialist cell lines and process development for bio-pharmaceutical products.

Meet us at the Animal Health Investment in London, 22nd and 23rd February, at the Millennium London Mayfair Hotel or contact us previously for a personal meeting! We look forward to meeting you!